Search
Zongertinib
go.drugbank.com/drugs/DB18762ApprovedInvestigationalZongertinib is a selective, irreversible tyrosine kinase inhibitor that targets human epidermal growth factor receptor 2 (HER2). It covalently binds to the HER2 receptor, including exon 20 insertions, and inhibits downstream signaling pa...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesDeuruxolitinib
go.drugbank.com/drugs/DB18847ApprovedInvestigationalDeuruxolitinib is a deuterated form of ruxolitinib that selectively inhibits Janus kinases (JAK) JAK1 and JAK2. Deuteration allows the drug to circumvent extensive oxidative metabolism around the cyclopentyl ring, which increases the dur...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesSunvozertinib
go.drugbank.com/drugs/DB18925InvestigationalSunvozertinib is an irreversible and selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. EGFR is a transmembrane protein with cytoplasmic kinase activity commonly expressed by non-small cell lung carcinomas (NSCL...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesSuzetrigine
go.drugbank.com/drugs/DB18927ApprovedInvestigationalSuzetrigine is a NaV1.8 voltage-gated sodium channel blocker with analgesic properties NaV1.8 is abundantly expressed in peripheral sensory nerves to play a role in pain signal transmission, making it a desirable therapeutic target for t...
Categories: P-glycoprotein substrates, Cytochrome P-450 CYP2B6 InducersOrforglipron
go.drugbank.com/drugs/DB18964ApprovedInvestigationalOrforglipron is a first-in-class oral, non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist. Developed to circumvent the adherence barriers and strict administration requirements of peptide-based GLP-1 therapies, its small-molecu...
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesBaxdrostat
go.drugbank.com/drugs/DB19090ApprovedInvestigationalBaxdrostat is an orally bioavailable, highly selective, first-in-class small-molecule aldosterone synthase inhibitor (ASI) designed to block the production of aldosterone . It targets aldosterone excess, a primary underlying driver of tr...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesCandicidin
go.drugbank.com/drugs/DB01152ApprovedInvestigationalWithdrawnCandicidin is an antibiotic obtained from a streptomyces (Streptomyces griseus) and active against some fungi of the genus Candida (C. albicans). Candicidin is administered intravaginally in the treatment of vulvovaginal candidiasis.
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsGemifloxacin
go.drugbank.com/drugs/DB01155ApprovedInvestigationalGemifloxacin is a quinolone antibacterial agent with a broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. It is available in oral formulations. Gemi...
Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme InhibitorsTerazosin
go.drugbank.com/drugs/DB01162ApprovedInvestigationalTerazosin is a quinazoline derivative alpha-1-selective adrenergic blocking agent indicated for benign prostatic hyperplasia and hypertension[FDA Label] . Terazosin blocks adrenaline's action on alpha-1 adrenergic receptors, causing rela...
Categories: P-glycoprotein inhibitorsProducts: TERAZOSINA MYLAN GENERICS, TERAZOSINA DOC GENERICICyclizine
go.drugbank.com/drugs/DB01176ApprovedWithdrawnA histamine H1 antagonist given by mouth or parenterally for the control of postoperative and drug-induced vomiting and in motion sickness. (From Martindale, The Extra Pharmacopoeia, 30th ed, p935)
Categories: Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 Enzyme Inhibitors